{
  "extraction_metadata": {
    "timestamp": "2025-09-10T11:28:11.221325",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 10,
    "total_picos": 29
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), mRECIST response, complication incidence, symptoms (fatigue, pain, jaundice, fever, abdominal swelling; measured by EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), health-related quality of life (measured by global health status, function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), mRECIST response, complication incidence, symptoms (fatigue, pain, jaundice, fever, abdominal swelling; measured by EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), health-related quality of life (measured by global health status, function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reactions, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), mRECIST response, complication incidence, symptoms (fatigue, pain, jaundice, fever, abdominal swelling; measured by EORTC QLQ-HCC18), health status (measured by EQ-5D VAS), health-related quality of life (measured by global health status, function scales of EORTC QLQ-C30 and EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5985
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, measured from date of cause of death to end date of study, with censoring at last known alive date), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life (assessed using EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), pharmacokinetic parameters, safety assessments (including vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography), adverse events (graded according to National Cancer Institute criteria), rate of grade 3 and 4 adverse reactions, treatment-related mortality, discontinuation due to adverse events, dose reduction due to adverse events, dropout rate for toxicity"
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, measured from date of cause of death to end date of study, with censoring at last known alive date), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life (assessed using EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), pharmacokinetic parameters, safety assessments (including vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography), adverse events (graded according to National Cancer Institute criteria), rate of grade 3 and 4 adverse reactions, treatment-related mortality, discontinuation due to adverse events, dose reduction due to adverse events, dropout rate for toxicity"
        },
        {
          "Population": "patients with hepatocellular carcinoma that was unresectable, diagnosed or histologically, or clinically confirmed according to the Assessment for the Study of Liver Diseases criteria. Modified RECIST criteria were applied. Patients were stage B or C at the Barcelona Liver Cancer Clinic, had a PS or Eastern Cooperative Oncology Group (ECOG) grade score of 0 or 1 or INFARMED, I.P.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, measured from date of cause of death to end date of study, with censoring at last known alive date), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life (assessed using EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), pharmacokinetic parameters, safety assessments (including vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography), adverse events (graded according to National Cancer Institute criteria), rate of grade 3 and 4 adverse reactions, treatment-related mortality, discontinuation due to adverse events, dose reduction due to adverse events, dropout rate for toxicity"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5019
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, patient-reported outcomes, adverse events (including serious adverse events and adverse reactions leading to discontinuation), health-related quality of life (quality of life weights, quality-of-life data), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, post-progression survival (PPS), health state utility values"
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, patient-reported outcomes, adverse events (including serious adverse events and adverse reactions leading to discontinuation), health-related quality of life (quality of life weights, quality-of-life data), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, post-progression survival (PPS), health state utility values"
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, patient-reported outcomes, adverse events (including serious adverse events and adverse reactions leading to discontinuation), health-related quality of life (quality of life weights, quality-of-life data), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, post-progression survival (PPS), health state utility values"
        },
        {
          "Population": "patients with HCC having a non viral etiology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq plus bevacizumab",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, patient-reported outcomes, adverse events (including serious adverse events and adverse reactions leading to discontinuation), health-related quality of life (quality of life weights, quality-of-life data), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY, cost-benefit analysis), resource use estimates, post-progression survival (PPS), health state utility values"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6223
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival, progression-free survival, time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        },
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival, progression-free survival, time to radiological disease progression, time to symptomatic disease progression (measured by FHSI-8 questionnaire), adverse events (including serious adverse events such as diarrhoea and hand-foot skin reaction), discontinuation of treatment due to adverse events, health-related quality of life, cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5788
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma in whom intentionally curative treatment or (continuation of) locoregional or local palliative treatment is not possible or is considered not to be medically appropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease for at least 16 weeks, adverse reactions (including serious adverse reactions and grade 3/4 adverse reactions such as hypertension, diarrhoea, lymphoedema, abdominal pain, hand-foot skin reaction), safety and tolerability in patients with hepatic dysfunction, cost-effectiveness analysis"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5588
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria for liver disease, duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria for liver disease, duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients with unresectable CHC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria for liver disease, duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria for liver disease, duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        },
        {
          "Population": "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab with bevacizumab",
          "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 criteria or death from any cause), objective response rate (percentage of patients with partial or complete response) by RECIST 1.1 and modified RECIST (mRECIST) criteria for liver disease, duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (based on EORTC QLQ-C30 and EORTC QLQ-HCC18 questionnaires), time to patient-reported impairment of quality of life (EORTC QLQ-C30 full scale, fitness sub-scale, and functional role subscale), adverse events (including serious adverse events, grade 5 adverse events, and specific adverse events such as gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus), discontinuation or dose modification due to adverse events, need for use of medical resources"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 8377
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause, with censoring at cut-off date or last contact), progression-free survival (PFS, defined as time from randomization to disease progression or death), time to progression (defined as time from randomization to date of disease progression), objective response rate (ORR), disease control rate, clinical benefit rate, adverse events (including serious adverse events, grade 3 adverse reactions, treatment-related deaths, and specific events such as hepatotoxicity, hypertension, loss of appetite, weight loss, haemorrhagic and thromboembolic events, hypothyroidism, proteinuria, hand-foot syndrome, fatigue, diarrhoea, dysphonia, alopecia), discontinuation of treatment due to adverse events, health-related quality of life (assessed using EQ5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires)"
        },
        {
          "Population": "patients with unresectable liver cell carcinomas",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause, with censoring at cut-off date or last contact), progression-free survival (PFS, defined as time from randomization to disease progression or death), time to progression (defined as time from randomization to date of disease progression), objective response rate (ORR), disease control rate, clinical benefit rate, adverse events (including serious adverse events, grade 3 adverse reactions, treatment-related deaths, and specific events such as hepatotoxicity, hypertension, loss of appetite, weight loss, haemorrhagic and thromboembolic events, hypothyroidism, proteinuria, hand-foot syndrome, fatigue, diarrhoea, dysphonia, alopecia), discontinuation of treatment due to adverse events, health-related quality of life (assessed using EQ5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires)"
        },
        {
          "Population": "a very select population (Child-Pugh A, ECOG 0 or 1) with no histological evidence of hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS, defined as time from randomization to death from any cause, with censoring at cut-off date or last contact), progression-free survival (PFS, defined as time from randomization to disease progression or death), time to progression (defined as time from randomization to date of disease progression), objective response rate (ORR), disease control rate, clinical benefit rate, adverse events (including serious adverse events, grade 3 adverse reactions, treatment-related deaths, and specific events such as hepatotoxicity, hypertension, loss of appetite, weight loss, haemorrhagic and thromboembolic events, hypothyroidism, proteinuria, hand-foot syndrome, fatigue, diarrhoea, dysphonia, alopecia), discontinuation of treatment due to adverse events, health-related quality of life (assessed using EQ5D-3L, EORTC QLQ-C30, and EORTC QLQ-HCC18 questionnaires)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7963
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), adverse events (including serious adverse events and grade 3 or 4 adverse events such as hand-foot skin reaction, diarrhoea, rash or skin desquamation, fatigue, weight loss, hypertension, decreased appetite, hypocalcaemia, increased ALT activity), discontinuation due to adverse events, number needed to harm (NNH), number needed to treat (NNT), health-related quality of life (measured by EQ-5D and EQ VAS, including dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and a 0-100 visual analogue scale), quality of life (measured by FACT-G questionnaire, covering physical, family/social, emotional, and functional well-being), deaths (including treatment-emergent deaths), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7298
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health-related quality of life (assessed by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (EQ-5D VAS), symptoms (fatigue, pain, jaundice, fever, abdominal swelling assessed by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health-related quality of life (assessed by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (EQ-5D VAS), symptoms (fatigue, pain, jaundice, fever, abdominal swelling assessed by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health-related quality of life (assessed by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (EQ-5D VAS), symptoms (fatigue, pain, jaundice, fever, abdominal swelling assessed by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        },
        {
          "Population": "HCC patients with PVT",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "all-cause mortality (death due to any cause), overall survival (OS), tumor response rate, adverse events (including grade III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation), quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), health-related quality of life (assessed by EORTC QLQ-C30 and EORTC QLQ-HCC18), health status (EQ-5D VAS), symptoms (fatigue, pain, jaundice, fever, abdominal swelling assessed by EORTC QLQ-HCC18), disease recurrence, length of hospital stay, complications, local control, days of missed work, discontinuation due to adverse events"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6056
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), time to response, duration of response, disease control rate (DCR, mRECIST), clinical benefit rate (CBR), adverse events (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in more than a specified proportion of patients), health-related quality of life (HRQoL, measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires), time to clinically meaningful deterioration in HRQoL (including domains such as role functioning, pain, diarrhoea, nutrition, and body image, measured by EORTC QLQ-C30 and QLQ-HCC18), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety, resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER)"
        },
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC not previously treated systemically.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), time to response, duration of response, disease control rate (DCR, mRECIST), clinical benefit rate (CBR), adverse events (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in more than a specified proportion of patients), health-related quality of life (HRQoL, measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires), time to clinically meaningful deterioration in HRQoL (including domains such as role functioning, pain, diarrhoea, nutrition, and body image, measured by EORTC QLQ-C30 and QLQ-HCC18), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety, resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER)"
        },
        {
          "Population": "Treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), time to response, duration of response, disease control rate (DCR, mRECIST), clinical benefit rate (CBR), adverse events (including serious adverse events, treatment-emergent adverse events, adverse events leading to discontinuation, adverse events occurring in more than a specified proportion of patients), health-related quality of life (HRQoL, measured by EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D questionnaires), time to clinically meaningful deterioration in HRQoL (including domains such as role functioning, pain, diarrhoea, nutrition, and body image, measured by EORTC QLQ-C30 and QLQ-HCC18), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety, resource use estimates, cost-effectiveness (incremental cost-effectiveness ratio, ICER)"
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6855
    }
  }
}